Skip to main content
. Author manuscript; available in PMC: 2023 Nov 21.
Published in final edited form as: ACS Infect Dis. 2021 Aug 26;7(9):2591–2595. doi: 10.1021/acsinfecdis.1c00237

Table 1.

Catalytic efficiencies for Mpro substrates and analogs

Substrate Sequencea kcat (S−1) Km (μM) kcat/KM (M−1 s−1) Fold changeb
nsp4/5 TSAVLQ/SGFRKM 0.52 ± 0.07 41 ± 9 1.3 ± 0.3 × 104
nsp8/9 RVVKLQ/NNELMP 0.013 ± 0.001 36 ± 6 3.6 ± 0.7 × 102 1.0
nsp8/9 N1′A RVVKLQ/ANELMP 0.022 ± 0.001 22 ± 3 1.0 ± 0.1 × 103 2.9
nsp8/9 N2′A RVVKLQ/NAELMP 0.034 ± 0.002 46 ± 5 7.5 ±0.8 × 102 2.1
nsp8/9 N1′D RVVKLQ/DNELMP
nsp8/9 N2′D RVVKLQ/NDELMP 0.0029 ± 0.0001 19 ± 1 1.6 ± 1.2 × 102 0.4
a

Lys-DABCYL and Glu-EDANS and are appended to the N- and C-termini. Residues that differ from the wild-type sequence are bolded.

b

Fold change = (kcat/KM) nsp8/9 analog /(kcat/KM)nsp8/9